Andere Sprachen Genexine, Inc.

Aktien

A095700

KR7095700001

A095700

Schlusskurs Korea S.E. Andere Börsenplätze 00:00:00 26.04.2024			% 5 Tage	% 1. Jan.
7 280 ^KRW	-0,95 %		+3,41 %	-26,46 %

2023	Genexine, Inc. meldet Ergebnis für das dritte Quartal und die neun Monate bis zum 30. September 2023	CI
2023	Genexine, Inc. und PT Kalbe Genexine Biologics erhalten die erste Marktzulassung für das neuartige langwirksame Erythropoetin, Efepoetin alfa, von der indonesischen Lebensmittel- und Arzneimittelbehörde (BPOM)	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Genexine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14.11.
Genexine, Inc. and PT Kalbe Genexine Biologics Receives the First Market Approval for Novel Long-Acting Erythropoietin, Efepoetin Alfa, from the Indonesian Food and Drug Authority	23.10.23
Sector Update: Health Care Stocks Edge Higher Premarket Thursday	31.08.23
Sector Update: Health Care	31.08.23
Salesforce Earnings, Inflation Outlook Bolster Exchange-Traded Funds, Equity Futures Premarket Thursday	31.08.23
I-Mab's Phase 3 Trial of Growth Hormone Deficiency Drug Meets Primary Endpoint, Joint Venture Partner Says	31.08.23
Genexine Announces Positive Topline Results from the Multi-Center, Randomized, Open-Label, Active-Controlled Pivotal Phase 3 Study	31.08.23
Henlius Biotech Grants Hansizhuang License to Kalbe Genexine Biologics	28.08.23
Genexine, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14.08.23
Genexine abstract on GX-188E and GX-I7 triple combination therapy in HNSCC is released at 2023 ASCO Annual Meeting	29.05.23
Genexine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15.05.23
Genexine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	20.03.23
Genexine Receives Fast Track Designation from Korean Health Authority (MFDS) for its promising DNA vaccine for advanced cervical cancer	23.01.23
Genexine Receives Fast Track Designation from Korean Health Authority for Its Promising DNA Vaccine for Advanced Cervical Cancer	20.01.23
Genexine, Inc. to Present Final Phase 2 Clinical Data on Its Cervical Cancer Program Showing a 35.0% Overall Response Rate and Provide a Corporate Overview During JP Morgan Conference	09.01.23
Genexine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14.11.22
Genexine to Raise $70 Million via Share Issuance	26.09.22
Genexine’s Announces that DNA Vaccine Shows Significant Potential to Extend Survival in Late-Stage Cervical Cancer	08.09.22
Genexine selected for Late-Breaking Oral Presentation of Phase 2 Study of GX-188E in Combination with KEYTRUDA (pembrolizumab) in Cervical Cancer at European Society for Medical Oncology (ESMO) Congr	25.08.22
Genexine to Present Phase 2 Study of GX-188E in Combination with KEYTRUDA® (pembrolizumab) in Cervical Cancer at European Society for Medical Oncology Congress 2022	25.08.22

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Genexine, Inc.

Aktien

A095700

KR7095700001

A095700

Andere Sprachen

Filter